StockMacro
Company, fund or insider

Help

Menu

West Pharmaceutical Services

$390.30 +23% in 6 monthsMarket cap $27.2B

WST on XNYS, Health Care, West Pharmaceutical Services, Inc., job postings

Measures activity, not value. Not investment advice.

Net profit rose 30% to $638.9M and the stock is up 51% in 12 months.

  • GoodInstitutional holders rose 6.7% to 865 from 811 the quarter before
  • WatchCapital spending fell 38% to $39.1M in the latest quarter

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
10,800
Website
westpharma.com
Listed
NYSE, US
Last results
29 Oct 2026
Next results
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $874.5M, net income $214.0M.
Quarter to 31 Dec 2021: revenue $730.8M, net income $147.7MQuarter to 31 Dec 2021: revenue $730.8M, net income $147.7MQuarter to 31 Mar 2022: revenue $720.0M, net income $173.8MQuarter to 31 Mar 2022: revenue $720.0M, net income $173.8MQuarter to 30 Jun 2022: revenue $771.3M, net income $188.5MQuarter to 30 Jun 2022: revenue $771.3M, net income $188.5MQuarter to 30 Sep 2022: revenue $686.9M, net income $120.6MQuarter to 30 Sep 2022: revenue $686.9M, net income $120.6MQuarter to 31 Dec 2022: revenue $708.7M, net income $103.0MQuarter to 31 Dec 2022: revenue $708.7M, net income $103.0MQuarter to 31 Mar 2023: revenue $716.6M, net income $140.0MQuarter to 31 Mar 2023: revenue $716.6M, net income $140.0MQuarter to 30 Jun 2023: revenue $753.8M, net income $155.1MQuarter to 30 Jun 2023: revenue $753.8M, net income $155.1MQuarter to 30 Sep 2023: revenue $747.4M, net income $161.3MQuarter to 30 Sep 2023: revenue $747.4M, net income $161.3MQuarter to 31 Dec 2023: revenue $732.0M, net income $137.0MQuarter to 31 Dec 2023: revenue $732.0M, net income $137.0MQuarter to 31 Mar 2024: revenue $695.4M, net income $115.3MQuarter to 31 Mar 2024: revenue $695.4M, net income $115.3MQuarter to 30 Jun 2024: revenue $702.1M, net income $111.3MQuarter to 30 Jun 2024: revenue $702.1M, net income $111.3MQuarter to 30 Sep 2024: revenue $746.9M, net income $136.0MQuarter to 30 Sep 2024: revenue $746.9M, net income $136.0MQuarter to 31 Dec 2024: revenue $748.8M, net income $130.1MQuarter to 31 Dec 2024: revenue $748.8M, net income $130.1MQuarter to 31 Mar 2025: revenue $698.0M, net income $89.8MQuarter to 31 Mar 2025: revenue $698.0M, net income $89.8MQuarter to 30 Jun 2025: revenue $766.5M, net income $131.8MQuarter to 30 Jun 2025: revenue $766.5M, net income $131.8MQuarter to 30 Sep 2025: revenue $804.6M, net income $140.0MQuarter to 30 Sep 2025: revenue $804.6M, net income $140.0MQuarter to 31 Dec 2025: revenue $805.0M, net income $132.1MQuarter to 31 Dec 2025: revenue $805.0M, net income $132.1MQuarter to 31 Mar 2026: revenue $844.9M, net income $138.8MQuarter to 31 Mar 2026: revenue $844.9M, net income $138.8MQuarter to 30 Jun 2026: revenue $872.3M, net income $154.0MQuarter to 30 Jun 2026: revenue $872.3M, net income $154.0MQuarter to 30 Sep 2026: revenue $874.5M, net income $214.0MQuarter to 30 Sep 2026: revenue $874.5M, net income $214.0M
31 Dec 2021RevenueNet incometallest bar $874.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$874.5M$214.0M
30 Jun 2026$872.3M$154.0M
31 Mar 2026$844.9M$138.8M
31 Dec 2025$805.0M$132.1M
30 Sep 2025$804.6M$140.0M
30 Jun 2025$766.5M$131.8M
31 Mar 2025$698.0M$89.8M
31 Dec 2024$748.8M$130.1M
30 Sep 2024$746.9M$136.0M
30 Jun 2024$702.1M$111.3M
31 Mar 2024$695.4M$115.3M
31 Dec 2023$732.0M$137.0M
30 Sep 2023$747.4M$161.3M
30 Jun 2023$753.8M$155.1M
31 Mar 2023$716.6M$140.0M
31 Dec 2022$708.7M$103.0M
30 Sep 2022$686.9M$120.6M
30 Jun 2022$771.3M$188.5M
31 Mar 2022$720.0M$173.8M
31 Dec 2021$730.8M$147.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $3.4B $3.0B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +13% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $638.9M $491.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $8.91 $6.75
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 37.6% 35.6% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 23.0% 19.5% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 18.8% 16.3% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 21.2% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $453.4M $379.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $464.1M $628.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $202.9M $202.7M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$261.2M (net cash) -$425.8M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.07 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $42.61
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 42.6 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 8.0 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 7.9 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 9.2 2.8
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 0.22% 1.4%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
West Pharmaceutical ServicesWST (this company) $27.2B42.68.0+13%18.8%
DexComDXCM $29.6B29.95.8+13%19.4%
MedlineMDLN $32.5B36.61.1–2.9%
ResMedRMD $33.1B20.85.8+9.0%27.8%
SolventumSOLV $14.3B91.91.8-2.8%1.9%
GlaukosGKOS $14.0Bloss20.3+47%-24.6%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+8.7%

$874.5M vs $804.6M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-38%

$39.1M vs $63.3M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$5.4M

bought $0, sold $5.4M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+6.7%

865 13F filers vs 811

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

99%

68.7M shares held by 13F filers (30 Sep 2026) of 69.7M outstanding (21 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.6%

1.8M shares sold short (30 Oct 2026) of 69.7M outstanding (21 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.3

1.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-10%

2.0M shares sold short in the report before, 1.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

48%

48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+21%

17 vs 14 applications

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$170K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

35

35 articles in the last 7 days; its usual week has 5.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.4×

35 articles in the last 7 days; its usual week has 5.5.

Price $390.30 on 20 Nov 2026, +51% over 12 months (12-month range $230.95 to $417.80)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $6.6M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 17 published in the last 12 months, +21% on the 12 months before.
Revenue per quarter. Revenue $874.5M in the latest quarter, +8.7% on a year earlier.
Capital spending per quarter. Capital spending $39.1M in the latest quarter, -38% on a year earlier.
Institutional holders (13F filers). 865 13F filers reported holding it in the latest 13F quarter, +21% on a year earlier.
Lobbying spend. Lobbying spend: $170K published in the last 12 months, +13% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
26 Oct 20268-K and other filingsA major agreement ended
19 Oct 2026Lobbying filinglobbying engagement terminated (CLARK HILL PUBLIC STRATEGIES LLC)
1 Jun 20268-K and other filingsDirector or officer change
11 May 20268-K and other filingsMaterial cybersecurity incident
9 Mar 20268-K and other filingsDirector or officer change
9 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Sep 20258-K and other filingsDirector or officer change
21 Jul 20258-K and other filingsDirector or officer change
17 Jun 2025Sharp changeShort interest spike: short interest spike, 2.1M vs usual 1.4M (2025-05-30); 1.7x the same period a year earlier
3 Jun 2025Sharp changeShort interest spike: short interest spike, 2.2M vs usual 1.4M (2025-05-15); 2.0x the same period a year earlier
13 May 2025Sharp changeShort interest spike: short interest spike, 2.5M vs usual 1.3M (2025-04-30); 2.4x the same period a year earlier
24 Apr 20258-K and other filingsDirector or officer change
14 Apr 20258-K and other filingsDirector or officer change
11 Mar 20258-K and other filingsDirector or officer change
28 Feb 2025Lobbying filingnew lobbying registration (CLARK HILL PUBLIC STRATEGIES LLC)
11 Dec 20248-K and other filingsDirector or officer change
7 Oct 20248-K and other filingsDirector or officer change
7 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Apr 20248-K and other filingsDirector or officer change
26 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Oct 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 95.8M vs usual 70.8M (2023-09-30); 1.7x the same period a year earlier
16 May 2023Sharp changeMany funds opening a new position: many funds opening a new position, 103 vs usual 60 (2023-03-31); 1.8x the same period a year earlier
27 Jul 20228-K and other filingsDirector or officer change
12 May 20228-K and other filingsDirector or officer change
28 Feb 20228-K and other filingsDirector or officer change
28 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: -$3.0M published
Month from 1 Aug 2022: -$6.7M published
Month from 1 Dec 2022: -$10.5M published
Month from 1 Mar 2023: -$14.7M published
Month from 1 May 2023: -$24.1M published
Month from 1 Jun 2023: -$343K published
Month from 1 Aug 2023: -$39.3M published
Month from 1 Sep 2023: -$829K published
Month from 1 Nov 2023: -$384K published
Month from 1 Dec 2023: -$354K published
Month from 1 Feb 2024: -$2.6M published
Month from 1 Mar 2024: -$24.1M published
Month from 1 May 2024: -$24.2M published
Month from 1 Jun 2024: -$595K published
Month from 1 Aug 2024: -$9.9M published
Month from 1 Nov 2024: -$218K published
Month from 1 Apr 2026: -$1.1M published
Month from 1 Sep 2026: -$5.4M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Apr 2022: 7 published
Quarter from 1 Jul 2022: 12 published
Quarter from 1 Oct 2022: 5 published
Quarter from 1 Jan 2023: 4 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 4 published
Quarter from 1 Oct 2023: 9 published
Quarter from 1 Jan 2024: 6 published
Quarter from 1 Apr 2024: 2 published
Quarter from 1 Jul 2024: 8 published
Quarter from 1 Oct 2024: 6 published
Quarter from 1 Jan 2025: 4 published
Quarter from 1 Apr 2025: 5 published
Quarter from 1 Jul 2025: 2 published
Quarter from 1 Oct 2025: 3 published
Quarter from 1 Jan 2026: 3 published
Quarter from 1 Apr 2026: 3 published
Quarter from 1 Jul 2026: 7 published
Quarter from 1 Oct 2026: 4 published
Revenue per quarter
Quarter ended 31 Dec 2021: $730.8M, +26% on a year earlier; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $720.0M, +7.4% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $771.3M, +6.6% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $686.9M, -2.8% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $708.7M, -3.0% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $716.6M, -0.5% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $753.8M, -2.3% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $747.4M, +8.8% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $732.0M, +3.3% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $695.4M, -3.0% on a year earlier; public on 26 Apr 2024
Quarter ended 30 Jun 2024: $702.1M, -6.9% on a year earlier; public on 26 Jul 2024
Quarter ended 30 Sep 2024: $746.9M, -0.1% on a year earlier; public on 25 Oct 2024
Quarter ended 31 Dec 2024: $748.8M, +2.3% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $698.0M, +0.4% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Jun 2025: $766.5M, +9.2% on a year earlier; public on 25 Jul 2025
Quarter ended 30 Sep 2025: $804.6M, +7.7% on a year earlier; public on 24 Oct 2025
Quarter ended 31 Dec 2025: $805.0M, +7.5% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $844.9M, +21% on a year earlier; public on 24 Apr 2026
Quarter ended 30 Jun 2026: $872.3M, +14% on a year earlier; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $874.5M, +8.7% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $76.5M, +33% on a year earlier; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $65.8M, +20% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $66.1M, +16% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $57.8M, -11% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $94.9M, +24% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $82.1M, +25% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $75.4M, +14% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $95.8M, +66% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $108.7M, +15% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $90.6M, +10% on a year earlier; public on 26 Apr 2024
Quarter ended 30 Jun 2024: $100.2M, +33% on a year earlier; public on 26 Jul 2024
Quarter ended 30 Sep 2024: $81.3M, -15% on a year earlier; public on 25 Oct 2024
Quarter ended 31 Dec 2024: $104.9M, -3.5% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $71.3M, -21% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Jun 2025: $75.2M, -25% on a year earlier; public on 25 Jul 2025
Quarter ended 30 Sep 2025: $63.3M, -22% on a year earlier; public on 24 Oct 2025
Quarter ended 31 Dec 2025: $76.1M, -27% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $42.7M, -40% on a year earlier; public on 24 Apr 2026
Quarter ended 30 Jun 2026: $43.2M, -43% on a year earlier; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $39.1M, -38% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 644; public on 14 Feb 2022
31 Mar 2022 report: 664; public on 16 May 2022
30 Jun 2022 report: 607; public on 15 Aug 2022
30 Sep 2022 report: 576; public on 14 Nov 2022
31 Dec 2022 report: 574; public on 14 Feb 2023
31 Mar 2023 report: 637; public on 15 May 2023
30 Jun 2023 report: 666; public on 14 Aug 2023
30 Sep 2023 report: 696; public on 14 Nov 2023
31 Dec 2023 report: 725; public on 14 Feb 2024
31 Mar 2024 report: 738; public on 15 May 2024
30 Jun 2024 report: 735; public on 14 Aug 2024
30 Sep 2024 report: 682; public on 14 Nov 2024
31 Dec 2024 report: 707; public on 14 Feb 2025
31 Mar 2025 report: 680; public on 15 May 2025
30 Jun 2025 report: 697; public on 14 Aug 2025
30 Sep 2025 report: 716; public on 14 Nov 2025
31 Dec 2025 report: 770; public on 17 Feb 2026
31 Mar 2026 report: 738; public on 15 May 2026
30 Jun 2026 report: 811; public on 14 Aug 2026
30 Sep 2026 report: 865; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2025: $50K published
Quarter from 1 Jul 2025: $50K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $50K published
Quarter from 1 Jul 2026: $50K published
Quarter from 1 Oct 2026: $20K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $39.1M (30 Sep 2026), 47% below its normal quarter of $73.2M; higher than 59% of its own history.
  • Insider net buying (open market): Insiders sold a net $6.6M in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 17 published in the last 12 months, +21% on the 12 months before.
  • Revenue per quarter: Revenue $874.5M in the latest quarter, +8.7% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 70 insider trades

Last 90 days: 2 sales, $5.4M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
15 Sep 2026Annette F FavoriteSr. VP & Chief HR OfficerSellplanned in advance (10b5-1); after exercising options7,524$355.03$2.7MForm 4
10 Sep 2026Annette F FavoriteSr. VP & Chief HR OfficerSellafter exercising options8,135$340.81$2.8MForm 4
29 Apr 2026Chad WintersVP, Chief Accounting OfficerSellafter exercising options896$300.67$269KForm 4
29 Apr 2026Annette F FavoriteSr. VP & Chief HR OfficerSellafter exercising options2,817$305.20$860KForm 4
31 Oct 2024Charles WitherspoonVP & TreasurerSellafter exercising options703$310.40$218KForm 4
21 Aug 2024Charles WitherspoonVP & TreasurerSellafter exercising options1,029$300.00$309KForm 4
21 Aug 2024Thomas W HofmannDirectorSell617$365.92$226KForm 4
8 Aug 2024Eric Mark GreenPresident, CEO and Board ChairSellplanned in advance (10b5-1); after exercising options30,732$304.71$9.4MForm 4

865 institutions reported shares at the end of Q3 2026, 99% of the shares outstanding; 118 opened a position, 63 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.6.7M9.62%$2.5B+51K+0.8%
FMR LLC (Fidelity)6.0M8.60%$2.2B+2.4M+68%
Vanguard Capital Management LLC4.6M6.61%$1.7B-7,312-0.2%
Vanguard Portfolio Management LLC4.1M5.93%$1.5B+114K+2.8%
State Street Corp3.3M4.78%$1.2B-19K-0.6%
Artisan Partners Limited Partnership2.0M2.88%$744.4M-404K-17%
Geode Capital Management, LLC1.9M2.78%$715.2M+33K+1.7%
Bank of New York Mellon Corp1.7M2.50%$644.7M-305K-15%
Morgan Stanley1.6M2.26%$583.7M-8,120-0.5%
T. Rowe Price Investment Management, Inc.1.6M2.24%-248K-14%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 27 Sep 2013. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
27 Sep 2013Department of DefenseDepartment of the Army$4.0MIGF::CT::IGFUSAspending

Company events

All 43 company events

In 12 months: 2 director or officer changes, 2 major agreements, 1 cybersecurity incident, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
26 Oct 2026Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
14 Jul 2026Signed a major agreement8-K
1 Jun 2026Director or officer change8-K
11 May 2026Material cybersecurity incident8-K
9 Mar 2026Director or officer change8-K
11 Sep 2025Director or officer change8-K
21 Jul 2025Director or officer change8-K
24 Apr 2025Director or officer change8-K

Reported lobbying spend: $20K in Q3 2026, $50K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Jul 2026EndedClark Hill Public Strategies LLCfor West Pharmaceutical Services, Inc.Matters relating to the pharmaceutical manufacturing and supply chain security.MED, TAR, TradeFiling
24 Jan 2025NewClark Hill Public Strategies LLCfor West Pharmaceutical Services, Inc.Matters relating to tariffs, pharmaceuticals, and the medical industry.TAR, Trade, MEDFiling
31 Dec 2020EndedBryan Cave Leighton Paisner LLPfor West Pharmaceutical Services, Inc.Issues related to containment and delivery systems for injectable medicine.PharmacyFiling
1 Jun 2020NewBryan Cave Leighton Paisner LLPfor West Pharmaceutical Services, Inc.Issues pertaining to containment and delivery systems for injectable medicine.PharmacyFiling

Layoff notices

All 1 layoff notices

No notice in 12 months; the latest is dated 8 Oct 2009. State WARN notices.

NoticeSiteWorkersJobs endSource
8 Oct 2009West CorporationWinnebago County, IL2541 Dec 2009closureNotice

The 5 newest of 275 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

1 Jun 2021confirmed

Confirmed across sources Filings + Financials and Short interest and volume

West Pharmaceutical Services (WST): reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year, while it had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year. Two unrelated kinds of activity within 91 days.

  • Financials: Quarterly capital spending jump, became public on 4 May 2021
  • Financials: Quarterly revenue change, became public on 4 May 2021
  • Short interest and volume: Short interest spike, became public on 26 May 2021
  • Short interest and volume: Short interest spike, became public on 10 Jun 2021
  • Short interest and volume: Short interest spike, became public on 26 Jun 2021
  • Short interest and volume: Short interest spike, became public on 13 Jul 2021
  • Financials: Quarterly revenue change, became public on 3 Aug 2021
2019-03-31: $443.5M2019-06-30: $469.7M2019-09-30: $456.1M2019-12-31: $470.6M2020-03-31: $491.5M2020-06-30: $527.2M2020-09-30: $548.0M2020-12-31: $580.2M2021-03-31: $670.7M
The quarter ended 31 Mar 2021 against the 8 quarters before it. this quarterearliernormal: $481.1M
See the evidence (7 changes)

Financials: Quarterly capital spending jump became public on 4 May 2021

West Pharmaceutical Services spent $54.7M on capital projects in the quarter ended 31 Mar 2021, 1.7× the same quarter last year.

This period
$54.7M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$34.6M
Typical spread (median absolute deviation)
$4.4M
How far from its usual level
+3.1
Same quarter last year
$32.1M
History used
4,200 days
2019-03-31: $28.8M2019-06-30: $28.3M2019-09-30: $31.7M2019-12-31: $37.6M2020-03-31: $32.1M2020-06-30: $37.1M2020-09-30: $47.5M2020-12-31: $57.7M2021-03-31: $54.7M
the quarter ended 31 Mar 20218 earlier quartersnormal: $34.6M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Financials: Quarterly revenue change became public on 4 May 2021

West Pharmaceutical Services reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year.

This period
$670.7M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$481.1M
Typical spread (median absolute deviation)
$31.2M
How far from its usual level
+3.9
Same quarter last year
$491.5M
History used
4,292 days
2019-03-31: $443.5M2019-06-30: $469.7M2019-09-30: $456.1M2019-12-31: $470.6M2020-03-31: $491.5M2020-06-30: $527.2M2020-09-30: $548.0M2020-12-31: $580.2M2021-03-31: $670.7M
the quarter ended 31 Mar 20218 earlier quartersnormal: $481.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 26 May 2021

West Pharmaceutical Services had 1.0M shares sold short in the 14 May 2021 report, 1.4× the same report last year.

This period
1.0M (the 14 May 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
50K
How far from its usual level
+4.3
Same report last year
726K
History used
1,232 days
2020-05-15: 726K2020-05-29: 701K2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M
the 14 May 2021 report24 earlier reportsnormal: 699K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Jun 2021

West Pharmaceutical Services had 1.0M shares sold short in the 28 May 2021 report, 1.4× the same report last year.

This period
1.0M (the 28 May 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
57K
How far from its usual level
+3.7
Same report last year
701K
History used
1,246 days
2020-05-29: 701K2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M
the 28 May 2021 report24 earlier reportsnormal: 699K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jun 2021

West Pharmaceutical Services had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year.

This period
1.1M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.5
Same report last year
914K
History used
1,264 days
2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M2021-06-15: 1.1M
the 15 Jun 2021 report24 earlier reportsnormal: 699K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Jul 2021

West Pharmaceutical Services had 1.1M shares sold short in the 30 Jun 2021 report, 1.2× the same report last year.

This period
1.1M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.4
Same report last year
916K
History used
1,279 days
2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M2021-06-15: 1.1M2021-06-30: 1.1M
the 30 Jun 2021 report24 earlier reportsnormal: 699K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 3 Aug 2021

West Pharmaceutical Services reported revenue of $723.6M for the quarter ended 30 Jun 2021, 1.4× the same quarter last year.

This period
$723.6M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$509.4M
Typical spread (median absolute deviation)
$39.2M
How far from its usual level
+3.7
Same quarter last year
$527.2M
History used
4,383 days
2019-06-30: $469.7M2019-09-30: $456.1M2019-12-31: $470.6M2020-03-31: $491.5M2020-06-30: $527.2M2020-09-30: $548.0M2020-12-31: $580.2M2021-03-31: $670.7M2021-06-30: $723.6M
the quarter ended 30 Jun 20218 earlier quartersnormal: $509.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 26 Oct 2026Filings record

    A major agreement ended

  2. 19 Oct 2026Lobbying record

    WEST PHARMACEUTICAL SERVICES, INC.: lobbying engagement terminated (CLARK HILL PUBLIC STRATEGIES LLC) (dated 31 Jul 2026)

  3. 1 Jun 2026Filings record

    Director or officer change

  4. 11 May 2026Filings record

    Material cybersecurity incident

  5. 9 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 9 Mar 2026Filings record

    Director or officer change

  7. 11 Sep 2025Filings record

    Director or officer change

  8. 7 Aug 2025Institutional holdings record

    GENERATION INVESTMENT MANAGEMENT LLP opened a $255.0M position (2025Q2 13F)

  9. 21 Jul 2025Filings record

    Director or officer change

  10. 11 Jun 2025Short interest and volume change

    had 2.1M shares sold short in the 30 May 2025 report, 1.7× the same report last year.

    Same report last year: 1.3M; its normal report is 1.4M.

    See the evidence
    This period
    2.1M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    1.4M
    Typical spread (median absolute deviation)
    144K
    How far from its usual level
    +3.5
    Same report last year
    1.3M
    History used
    2,709 days
    2024-05-31: 1.3M2024-06-14: 1.2M2024-06-28: 1.2M2024-07-15: 1.2M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.4M2024-10-15: 1.5M2024-10-31: 1.4M2024-11-15: 1.3M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.5M2025-01-31: 1.3M2025-02-14: 1.2M2025-02-28: 1.4M2025-03-14: 1.5M2025-03-31: 1.4M2025-04-15: 1.4M2025-04-30: 2.5M2025-05-15: 2.2M2025-05-30: 2.1M
    the 30 May 2025 report24 earlier reportsnormal: 1.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 28 May 2025Short interest and volume change

    had 2.2M shares sold short in the 15 May 2025 report, 2.0× the same report last year.

    Same report last year: 1.1M; its normal report is 1.4M.

    See the evidence
    This period
    2.2M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    1.4M
    Typical spread (median absolute deviation)
    137K
    How far from its usual level
    +4.4
    Same report last year
    1.1M
    History used
    2,694 days
    2024-05-15: 1.1M2024-05-31: 1.3M2024-06-14: 1.2M2024-06-28: 1.2M2024-07-15: 1.2M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.4M2024-10-15: 1.5M2024-10-31: 1.4M2024-11-15: 1.3M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.5M2025-01-31: 1.3M2025-02-14: 1.2M2025-02-28: 1.4M2025-03-14: 1.5M2025-03-31: 1.4M2025-04-15: 1.4M2025-04-30: 2.5M2025-05-15: 2.2M
    the 15 May 2025 report24 earlier reportsnormal: 1.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 10 May 2025Short interest and volume change

    had 2.5M shares sold short in the 30 Apr 2025 report, 2.4× the same report last year.

    Same report last year: 1.0M; its normal report is 1.3M.

    See the evidence
    This period
    2.5M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    125K
    How far from its usual level
    +6.5
    Same report last year
    1.0M
    History used
    2,679 days
    2024-04-30: 1.0M2024-05-15: 1.1M2024-05-31: 1.3M2024-06-14: 1.2M2024-06-28: 1.2M2024-07-15: 1.2M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.5M2024-09-13: 1.6M2024-09-30: 1.4M2024-10-15: 1.5M2024-10-31: 1.4M2024-11-15: 1.3M2024-11-29: 1.2M2024-12-13: 1.2M2024-12-31: 1.5M2025-01-15: 1.5M2025-01-31: 1.3M2025-02-14: 1.2M2025-02-28: 1.4M2025-03-14: 1.5M2025-03-31: 1.4M2025-04-15: 1.4M2025-04-30: 2.5M
    the 30 Apr 2025 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 24 Apr 2025Filings record

    Director or officer change

  14. 14 Apr 2025Filings record

    Director or officer change

  15. 11 Mar 2025Filings record

    Director or officer change

  16. 28 Feb 2025Lobbying record

    WEST PHARMACEUTICAL SERVICES, INC.: new lobbying registration (CLARK HILL PUBLIC STRATEGIES LLC) (dated 24 Jan 2025)

  17. 11 Dec 2024Filings record

    Director or officer change

  18. 7 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 7 Oct 2024Filings record

    Director or officer change

  20. 26 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 26 Apr 2024Filings record

    Director or officer change

  22. 31 Oct 2023Financials change

    spent $95.8M on capital projects in the quarter ended 30 Sep 2023, 1.7× the same quarter last year.

    Same quarter last year: $57.8M; its normal quarter is $70.8M.

    See the evidence
    This period
    $95.8M (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $70.8M
    Typical spread (median absolute deviation)
    $5.6M
    How far from its usual level
    +3.0
    Same quarter last year
    $57.8M
    History used
    5,113 days
    2021-09-30: $65.3M2021-12-31: $76.5M2022-03-31: $65.8M2022-06-30: $66.1M2022-09-30: $57.8M2022-12-31: $94.9M2023-03-31: $82.1M2023-06-30: $75.4M2023-09-30: $95.8M
    the quarter ended 30 Sep 20238 earlier quartersnormal: $70.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 15 May 2023Institutional holdings change

    saw 103 13F filers open a new position in the quarter ended 31 Mar 2023, 1.8× the same quarter last year.

    Same quarter last year: 56; its normal quarter is 60.

    See the evidence
    This period
    103 (the quarter ended 31 Mar 2023)
    Normal quarter (median of 8 earlier)
    60
    Typical spread (median absolute deviation)
    8
    How far from its usual level
    +3.6
    Same quarter last year
    56
    History used
    3,469 days
    2021-03-31: 602021-06-30: 862021-09-30: 772021-12-31: 842022-03-31: 562022-06-30: 482022-09-30: 602022-12-31: 592023-03-31: 103
    the quarter ended 31 Mar 20238 earlier quartersnormal: 60

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  24. 27 Jul 2022Filings record

    Director or officer change

  25. 12 May 2022Filings record

    Director or officer change

  26. 28 Feb 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 28 Feb 2022Filings record

    Director or officer change

  28. 23 Aug 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 23 Aug 2021Filings record

    Director or officer change

  30. 3 Aug 2021Financials change

    reported revenue of $723.6M for the quarter ended 30 Jun 2021, 1.4× the same quarter last year.

    Same quarter last year: $527.2M; its normal quarter is $509.4M.

    See the evidence
    This period
    $723.6M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $509.4M
    Typical spread (median absolute deviation)
    $39.2M
    How far from its usual level
    +3.7
    Same quarter last year
    $527.2M
    History used
    4,383 days
    2019-06-30: $469.7M2019-09-30: $456.1M2019-12-31: $470.6M2020-03-31: $491.5M2020-06-30: $527.2M2020-09-30: $548.0M2020-12-31: $580.2M2021-03-31: $670.7M2021-06-30: $723.6M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $509.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  31. 13 Jul 2021Short interest and volume change

    had 1.1M shares sold short in the 30 Jun 2021 report, 1.2× the same report last year.

    Same report last year: 916K; its normal report is 699K.

    See the evidence
    This period
    1.1M (the 30 Jun 2021 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    65K
    How far from its usual level
    +4.4
    Same report last year
    916K
    History used
    1,279 days
    2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M2021-06-15: 1.1M2021-06-30: 1.1M
    the 30 Jun 2021 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 26 Jun 2021Short interest and volume change

    had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year.

    Same report last year: 914K; its normal report is 699K.

    See the evidence
    This period
    1.1M (the 15 Jun 2021 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    65K
    How far from its usual level
    +4.5
    Same report last year
    914K
    History used
    1,264 days
    2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M2021-06-15: 1.1M
    the 15 Jun 2021 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 10 Jun 2021Short interest and volume change

    had 1.0M shares sold short in the 28 May 2021 report, 1.4× the same report last year.

    Same report last year: 701K; its normal report is 699K.

    See the evidence
    This period
    1.0M (the 28 May 2021 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    57K
    How far from its usual level
    +3.7
    Same report last year
    701K
    History used
    1,246 days
    2020-05-29: 701K2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M
    the 28 May 2021 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 1 Jun 2021several at once

    reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year, while it had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year. Two unrelated kinds of activity within 91 days.

    See the evidence (7 changes)

    Financials: Quarterly capital spending jump became public on 4 May 2021

    West Pharmaceutical Services spent $54.7M on capital projects in the quarter ended 31 Mar 2021, 1.7× the same quarter last year.

    This period
    $54.7M (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    $34.6M
    Typical spread (median absolute deviation)
    $4.4M
    How far from its usual level
    +3.1
    Same quarter last year
    $32.1M
    History used
    4,200 days
    2019-03-31: $28.8M2019-06-30: $28.3M2019-09-30: $31.7M2019-12-31: $37.6M2020-03-31: $32.1M2020-06-30: $37.1M2020-09-30: $47.5M2020-12-31: $57.7M2021-03-31: $54.7M
    the quarter ended 31 Mar 20218 earlier quartersnormal: $34.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Financials: Quarterly revenue change became public on 4 May 2021

    West Pharmaceutical Services reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year.

    This period
    $670.7M (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    $481.1M
    Typical spread (median absolute deviation)
    $31.2M
    How far from its usual level
    +3.9
    Same quarter last year
    $491.5M
    History used
    4,292 days
    2019-03-31: $443.5M2019-06-30: $469.7M2019-09-30: $456.1M2019-12-31: $470.6M2020-03-31: $491.5M2020-06-30: $527.2M2020-09-30: $548.0M2020-12-31: $580.2M2021-03-31: $670.7M
    the quarter ended 31 Mar 20218 earlier quartersnormal: $481.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 26 May 2021

    West Pharmaceutical Services had 1.0M shares sold short in the 14 May 2021 report, 1.4× the same report last year.

    This period
    1.0M (the 14 May 2021 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    50K
    How far from its usual level
    +4.3
    Same report last year
    726K
    History used
    1,232 days
    2020-05-15: 726K2020-05-29: 701K2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M
    the 14 May 2021 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Jun 2021

    West Pharmaceutical Services had 1.0M shares sold short in the 28 May 2021 report, 1.4× the same report last year.

    This period
    1.0M (the 28 May 2021 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    57K
    How far from its usual level
    +3.7
    Same report last year
    701K
    History used
    1,246 days
    2020-05-29: 701K2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M
    the 28 May 2021 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jun 2021

    West Pharmaceutical Services had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year.

    This period
    1.1M (the 15 Jun 2021 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    65K
    How far from its usual level
    +4.5
    Same report last year
    914K
    History used
    1,264 days
    2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M2021-06-15: 1.1M
    the 15 Jun 2021 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Jul 2021

    West Pharmaceutical Services had 1.1M shares sold short in the 30 Jun 2021 report, 1.2× the same report last year.

    This period
    1.1M (the 30 Jun 2021 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    65K
    How far from its usual level
    +4.4
    Same report last year
    916K
    History used
    1,279 days
    2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M2021-05-28: 1.0M2021-06-15: 1.1M2021-06-30: 1.1M
    the 30 Jun 2021 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 3 Aug 2021

    West Pharmaceutical Services reported revenue of $723.6M for the quarter ended 30 Jun 2021, 1.4× the same quarter last year.

    This period
    $723.6M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $509.4M
    Typical spread (median absolute deviation)
    $39.2M
    How far from its usual level
    +3.7
    Same quarter last year
    $527.2M
    History used
    4,383 days
    2019-06-30: $469.7M2019-09-30: $456.1M2019-12-31: $470.6M2020-03-31: $491.5M2020-06-30: $527.2M2020-09-30: $548.0M2020-12-31: $580.2M2021-03-31: $670.7M2021-06-30: $723.6M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $509.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  35. 26 May 2021Short interest and volume change

    had 1.0M shares sold short in the 14 May 2021 report, 1.4× the same report last year.

    Same report last year: 726K; its normal report is 699K.

    See the evidence
    This period
    1.0M (the 14 May 2021 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    50K
    How far from its usual level
    +4.3
    Same report last year
    726K
    History used
    1,232 days
    2020-05-15: 726K2020-05-29: 701K2020-06-15: 914K2020-06-30: 916K2020-07-15: 769K2020-07-31: 698K2020-08-14: 737K2020-08-31: 744K2020-09-15: 709K2020-09-30: 684K2020-10-15: 758K2020-10-30: 627K2020-11-13: 598K2020-11-30: 549K2020-12-15: 590K2020-12-31: 658K2021-01-15: 699K2021-01-29: 845K2021-02-12: 668K2021-02-26: 602K2021-03-15: 644K2021-03-31: 692K2021-04-15: 672K2021-04-30: 863K2021-05-14: 1.0M
    the 14 May 2021 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 6 May 2021Filings record

    Director or officer change

  37. 4 May 2021Financials change

    reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year.

    Same quarter last year: $491.5M; its normal quarter is $481.1M.

    See the evidence
    This period
    $670.7M (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    $481.1M
    Typical spread (median absolute deviation)
    $31.2M
    How far from its usual level
    +3.9
    Same quarter last year
    $491.5M
    History used
    4,292 days
    2019-03-31: $443.5M2019-06-30: $469.7M2019-09-30: $456.1M2019-12-31: $470.6M2020-03-31: $491.5M2020-06-30: $527.2M2020-09-30: $548.0M2020-12-31: $580.2M2021-03-31: $670.7M
    the quarter ended 31 Mar 20218 earlier quartersnormal: $481.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  38. 4 May 2021Financials change

    spent $54.7M on capital projects in the quarter ended 31 Mar 2021, 1.7× the same quarter last year.

    Same quarter last year: $32.1M; its normal quarter is $34.6M.

    See the evidence
    This period
    $54.7M (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    $34.6M
    Typical spread (median absolute deviation)
    $4.4M
    How far from its usual level
    +3.1
    Same quarter last year
    $32.1M
    History used
    4,200 days
    2019-03-31: $28.8M2019-06-30: $28.3M2019-09-30: $31.7M2019-12-31: $37.6M2020-03-31: $32.1M2020-06-30: $37.1M2020-09-30: $47.5M2020-12-31: $57.7M2021-03-31: $54.7M
    the quarter ended 31 Mar 20218 earlier quartersnormal: $34.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  39. 2 Mar 2021Financials change

    spent $57.7M on capital projects in the quarter ended 31 Dec 2020, 1.5× the same quarter last year.

    Same quarter last year: $37.6M; its normal quarter is $31.9M.

    See the evidence
    This period
    $57.7M (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    $31.9M
    Typical spread (median absolute deviation)
    $3.4M
    How far from its usual level
    +5.2
    Same quarter last year
    $37.6M
    History used
    4,110 days
    2018-12-31: $30.0M2019-03-31: $28.8M2019-06-30: $28.3M2019-09-30: $31.7M2019-12-31: $37.6M2020-03-31: $32.1M2020-06-30: $37.1M2020-09-30: $47.5M2020-12-31: $57.7M
    the quarter ended 31 Dec 20208 earlier quartersnormal: $31.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  40. 1 Mar 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 69 entries; narrow the window or the kind of data to see older ones.

Not listed: 174 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000105770
Ticker
WST
Domain
westpharma.com
Employer name
West Corporation, West Pharmaceutical Services, Inc. (2 unverified)
Hq location
PA|EXTON|19341 (1 unverified)
Lobbying client
west pharmaceutical services
Name
Tech Group Europe Limited, Tech Group Grand Rapids, Inc, TGPR Holdings Limited, WEST CO INC and 38 more
Uei
JP72MQBU2RJ4
Wikidata
Q124358903
  • DOL H-1B labor condition applications and PERM certifications524 data points20 Jan 2020 to 31 Aug 2026
  • Federal lobbying disclosures (LDA)4 records, 30 data points1 Jun 2020 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)141 records18 Feb 2016 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1347 data points31 Dec 2007 to 21 Oct 2026
  • SEC Form 4 insider transactions70 records, 228 data points24 Feb 2016 to 15 Sep 2026
  • FINRA short interest (twice monthly)627 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 75 data points4 Dec 2007 to 1 Feb 2021
  • WARN layoff notices (state labor agencies)1 record, 3 data points5 Oct 2009 to 8 Oct 2009